Autologous LN-145 in Patients With Metastatic Non-Small-Cell Lung Cancer (NCT04614103)
A Phase 2 Multicenter Study of Autologous Tumor Infiltrating Lymphocytes (TIL or LN-145) in Patients With Metastatic Non-Small-Cell Lung Cancer
🩺 Plain-English Summary (8th-Grade Level)
This is a prospective, open-label, multi-cohort, non-randomized, multicenter phase 2 study evaluating LN-145 in patients with metastatic non-small-cell lung cancer
Who can join: Review the eligibility criteria below.
Location: Banner Health MD Anderson — Gilbert, Arizona
Age range: 18 Years to 70 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (71 Sites)
Showing the first 25 of 71 sites.
- Banner Health MD Anderson — Gilbert, Arizona
- Sylvester Comprehensive Cancer Center — Miami, Florida
- H Lee Moffitt Cancer Center and Research Institute — Tampa, Florida
- Rush University Medical Center — Chicago, Illinois
- University of Illinois Hospital & Health Sciences System — Chicago, Illinois
- Advocate Aurora Health — Park Ridge, Illinois
- University of Louisville — Louisville, Kentucky
- University of Maryland — Baltimore, Maryland
- Karmanos Cancer Institute — Detroit, Michigan
- University of Minnesota — Minneapolis, Minnesota
- University of Nebraska Medical Center — Omaha, Nebraska
- MD Anderson Cooper — Camden, New Jersey
- New York University Langone Medical Center — New York, New York
- Memorial Sloan Kettering Cancer Center — New York, New York
- University of North Carolina — Chapel Hill, North Carolina
- Novant Health - Winston-Salem — Winston-Salem, North Carolina
- Sanford Roger Maris Cancer Center — Fargo, North Dakota
- University of Cincinnati Medical Center — Cincinnati, Ohio
- Ohio State University Comprehensive Cancer Center — Columbus, Ohio
- Oregon Health and Science University — Portland, Oregon
- Allegheny General Hospital — Natrona Heights, Pennsylvania
- Sanford Cancer Center — Sioux Falls, South Dakota
- Avera Medical Group Cancer Institute — Sioux Falls, South Dakota
- University of Tennessee Medical Center — Knoxville, Tennessee
- Baptist Cancer Center — Memphis, Tennessee
📞 Contact the Study Coordinator
Phone: (844) 845-4682
Email: Clinical.Inquiries@iovance.com
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Metastatic Non Small Cell Lung Cancer
- Phase 3 Study of MRTX849 (Adagrasib) vs Docetaxel in Patients With Advanced Non-Small Cell Lung Cancer With KRAS G12C Mutation — Cerritos, California
- Study of Dato-DXd Plus Pembrolizumab vs Pembrolizumab Alone in the First-line Treatment of Subjects With Advanced or Metastatic NSCLC Without Actionable Genomic Alterations — Chandler, Arizona
- Safety and Efficacy of Combining APL-101 With Frontline Osimertinib in Patients With EGFR-mutated Metastatic Non-small Cell Lung Cancer (NSCLC) — St Louis, Missouri
- Datopotamab Deruxtecan (Dato-DXd) and Pembrolizumab With or Without Platinum Chemotherapy in 1L Non-Small Cell Lung Cancer (TROPION-Lung07) — Daphne, Alabama
- MOv19-BBz CAR T Cells in FRa+ Cancers — Philadelphia, Pennsylvania
Explore by condition: All Metastatic Non Small Cell Lung Cancer clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.